DATA GRAPHICS | Data Byte
MS market dynamics: Ocrevus still king as Kesimpta sales boom
Plus: Briumvi shows signs of growth, while sales of oral therapies remain mostly flat
March 7, 2025 12:27 AM UTC
Among five multiple sclerosis therapies launched in recent years, only one — Novartis’ Kesimpta — appears to be on a trajectory that could challenge Roche’s market-leader Ocrevus. Other recent entrants, Briumvi from TG Therapeutics, Zeposia from BMS, and Vumerity from Biogen, have seen more modest uptake to date.
Roche (SIX:ROG; OTCQB:RHHBY) reported $7.6 billion in 2024 sales of Ocrevus ocrelizumab, a 6% rise over 2023, although its 4Q24 sales dipped slightly from the previous quarter...